Dogwood Therapeutics, Inc.
No SEC Form 4 filings for $DWTX in the last 30 days.
See all $DWTX insider activity →Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
Dogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled – - Commencement of Phase 2b Long-Term Extension Study to assess H
Dogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. DOGWOOD THERAPEUTICS, INC._June 16, 2026 0001818844 false --12-31 0001818844 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Da
Over the past 7 days, alphai's AI scored 1 news story mentioning DWTX (Dogwood Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent DWTX coverage spans financial news, market movers and earnings.
Trial enrollment progress and cash runway reduce near‑term execution risk, supporting upside.
Near-term catalyst is the fall 2026 topline readout for Halneuron Phase 2b, supported by new trial expansion and cash runway guidance.
The filing is a corporate-governance update with a dilutive-leaning signal via increased authorized shares, but no immediate financing terms are disclosed.
The company's upcoming participation in the H.C. Wainwright conference may positively influence investor sentiment and stock performance in the short term.
Dogwood Therapeutics is engaging in a significant investor event, potentially signaling positive developments or strategic initiatives. This could lead to increased investor interest and a short-term uptick in stock price.
alphai scores every news story that mentions DWTX with an AI model for sentiment and relevance, and aggregates insider trades from Dogwood Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.
3 min readDogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled – - Commencement of Phase 2b Long-Term Extension Study to assess H
6 min readDogwood Therapeutics, Inc. (DWTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. DOGWOOD THERAPEUTICS, INC._June 16, 2026 0001818844 false --12-31 0001818844 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Da
3 min readATLANTA, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc. DWTX ( the "Company" ) , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C. Wainwright 27th Annual Global ...
3 min readATLANTA, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc. ( Nasdaq: DWTX ) ( the "Company" ) , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C.
2 min readATLANTA, June 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc. ( Nasdaq: DWTX ) ( "Dogwood" or the "Company" ) , a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced that CEO, Greg Duncan, will present a ...
2 min readATLANTA, June 03, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc.
2 min readATLANTA, April 11, 2025 ( GLOBE NEWSWIRE ) -- Dogwood Therapeutics, Inc. ( Nasdaq: DWTX ) ( the "Company" ) , a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation ...
2 min read
